Biomarkers in Brain Disease, Volume 1180ISBN: 978-1-57331-772-6
Paperback
276 pages
December 2009, Wiley-Blackwell
|
Advances in biomarker development are revolutionizing the way we
study, diagnose and treat disease. However, progress in the
development and use of biomarkers for diseases of the central
nervous system has been limited by a number of difficulties --
including the inherent barriers associated with studying the brain.
Development of reliable biomarkers for brain disorders would
dramatically accelerate research on the etiology, pathophysiology,
disease progression, and therapeutic development of many very
prevalent and devastating diseases including Alzheimer's disease,
Parkinson's disease, multiple sclerosis, and others. International
experts in the field have contributed chapters to this volume that
discuss the latest advances in biomarker technologies and biomarker
development for brain disorders, as well as the logistical,
regulatory and funding challenges experienced by scientists working
on clinical trials for biomarkers
NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.com/nyas.
ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.